Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab, Bevacizumab, and SBRT for Unresectable Hepatocellular Carcinoma
NCT05096715Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2022
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Massachusetts General Hospital. Primary endpoint: Dose Limiting Toxicity Rate at 18 weeks. Started Aug 2022; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05096715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05096715.